Clinical Trials for Chemotherapy - cytotoxic
68 Open Trials
| Trial Type & Disease | Protocol No. & Open Date | Summary |
|---|---|---|
| Therapeutic Breast | VICCBRE1304 06/04/2013 | A Phase II Study Evaluating the Efficacy and Tolerability of Everolimus (RAD001) in Combination with Trastuzumab and Vinorelbine in the Treatment of Progressive HER2-Positive Breast Cancer Brain Metastases |
| Therapeutic Sarcoma | VICCSAR1124 05/31/2013 | A Randomized Controlled Study of YONDELIS (Trabectedin) or Dacarbazine for the Treatment of Advanced Liposarcoma or Leiomyosarcoma Previously Treated With an Anthracycline and Ifosfamide |
| Therapeutic Pancreatic | ECOGGIA021101 05/31/2013 | Neoadjuvant Folfirinox and Chemoradiation Followed by Definitive Surgery and Postoperative Gemcitabine for Patients with Borderline Resectable Pancreatic Adenocarcinoma: an Intergroup Single-Arm Pilot Study |
| Therapeutic Neuroendocrine; Pancreatic | VICCGI1250 04/09/2013 | A Phase I/II Study of the Combination of Temozolomide and Pazopanib in Advanced Pancreatic Neuroendocrine Tumors (PNET) |
| Therapeutic Pancreatic | ECOGGIS1115 03/21/2013 | Randomized Phase II Clinical Trial of AZD6244 Hydrogen Sulfate (NSC-748727) and MK-2206 (NSC-749607) vs. mFOLFOX in Patients with Metastatic Pancreatic Cancer after Prior Chemotherapy |
| Therapeutic Prostate | VICCURO1260 03/19/2013 | A Phase I Study of Cabazitaxel, Mitoxantrone, and Prednisone (CAMP) for Patients with Metastatic Castration-Resistant Prostate Cancer and no Prior Chemotherapy |
| Therapeutic Esophageal | VICCGI1211 03/08/2013 | Phase IB/II Study of Induction Chemotherapy with XELOX, followed by Radiation Therapy, Carboplatin and RAD001 in Patients with Esophageal Cancer |
| Therapeutic Esophageal | ECOGGIR1010 02/28/2013 | A Phase III Trial Evaluating the Addition of Trastuzumab to Trimodality Treatment of HER2-Overexpressing Esophageal Adenocarcinoma |
| Therapeutic Gastric/Gastroesophageal | VICCGI1283 02/14/2013 | A Randomized, Multicenter, Adaptive Phase II/III Study to Evaluate the Efficacy and Safety of Trastuzumab Emtansine (T-DM1) Versus Taxane (Docetaxel or Paclitaxel) in Patients with Previously Treated Locally Advanced or Metastatic HER2-Positive Gastric Cancer, Including Adenocarcinoma of the Gastroesophageal Junction |
| Therapeutic Gastric/Gastroesophageal | VICCGI1269 01/28/2013 | A Phase 3, Multicenter, Randomized, Double-Blind, Placebo Controlled Study of Rilotumumab (AMG 102) with Epirubicin, Cisplatin, and Capecitabine (ECX) as First-line Therapy in Advanced MET-Positive Gastric or Gastroesophageal Junction Adenocarcinoma |
| Therapeutic Lung | VICCTHN1281 01/23/2013 | An Open-Label Randomized Phase III Trial of BMS-936558 versus Docetaxel in Previously Treated Metastatic Non-squamous Non-small cell Lung Cancer (NSCLC) |
| Therapeutic Melanoma | VICCMEL12100 01/18/2013 | A Randomized, Open-Label Phase 3 Trial of BMS-936558 versus Investigator's Choice in Advanced (Unresectable or Metastatic) Melanoma Patients Progressing Post Anti-CTLA-4 Therapy. |
| Therapeutic Leukemia | VICCHEM1289 01/04/2013 | Phase III, Multicenter, Randomized, Trial of CPX-351 (Cytarabine: Daunorubicin) Liposome Injection Versus Cytarabine and Daunorubicin in Patients 60-75 Years of Age with Untreated High Risk (Secondary) AML |
| Therapeutic Lung; Small Cell | VICCTHN1189 12/14/2012 | Randomized, Multicenter, Double-Blind, Phase 3 Trial Comparing the Efficacy of Ipilimumab plus Etoposide/Platinum versus Etoposide/Platinum in Subjects with Newly Diagnosed Extensive-Stage Disease Small Cell Lung Cancer (ED-SCLC) |
| Therapeutic Breast | VICCBRE1270 11/20/2012 | A Phase II, Multi-Center, Open-Label, Neoadjuvant, Randomized Study of Weekly Paclitaxel with or without LCL161 in Patients with Triple Negative Breast Cancer |
| Therapeutic Pediatric Solid Tumors | COGACNS1123 11/04/2012 | Phase 2 Trial of Response-Based Radiation Therapy for Patients with Localized Central Nervous System Germ Cell Tumors (CNS GCT) |
| Therapeutic Neuro-Oncology | VICCNEU1216 10/02/2012 | An International, Randomized, Double-Blind, Controlled Study of Rindopepimut/GM-CSF with Adjuvant Temozolomide in Patients with Newly Diagnosed, Surgically Resected, EGFRvIII-positive Glioblastoma |
| Therapeutic Head/Neck | ECOGTHNR1016 09/25/2012 | Phase III Trial of Radiotherapy Plus Cetuximab Versus Chemoradiotherapy in HPV-Associated Oropharynx Cancer |
| Therapeutic Gynecologic; Ovarian | VICCGYN1206 09/25/2012 | A phase II randomized open label study of MM-121 in combination with paclitaxel versus paclitaxel alone in patients with platinum resistant/refractory advanced ovarian cancers |
| Therapeutic Pancreatic | ECOGGIR0848 09/12/2012 | A Phase III Trial Evaluating Both Erlotinib and Chemoradiation as Adjuvant Treatment for Patients with Resected Head of Pancreas Adenocarcinoma |
| Therapeutic Lung; Small Cell | VICCTHN1212 09/12/2012 | Randomized Phase II Study of Single Agent OSI-906, an Oral, Small Molecule, Tyrosine Kinase Inhibitor (TKI) of the Insulin Growth Factor-1 Receptor (IGF-1R) Versus Topotecan for the Treatment of Patients with Relapsed Small Cell Lung Cancer (SCLC) |
| Therapeutic Head/Neck | ECOGTHNR1008 09/07/2012 | A Randomized Phase II Study of Adjuvant Concurrent Radiation and Chemotherapy versus Radiation Alone in Resected High-Risk Malignant Salivary Gland Tumors |
| Therapeutic Lung | VICCTHN1122 08/21/2012 | Open label two-stage study of orally administered BKM120 in patients with metastatic non-small cell lung cancer with activated PI3K pathway |
| Therapeutic Leukemia | VICCHEM1151 08/17/2012 | Randomized Phase II Trial of Timed Sequential Therapy (TST) with Alvocidib (Flavopiridol), ara-C and mitoxantrone (FLAM) vs. "7+3" for Adults age 70 and Under with Newly Diagnosed Acute Myelogenous Leukemia (AML) |
| Therapeutic Sarcoma | VICCSAR1169 08/03/2012 | A Randomized Phase 3, Multicenter, Open-Label Study Comparing TH-302 in Combination with Doxorubicin vs. Doxorubicin Alone in Subjects with Locally Advanced Unresectable or Metastatic Soft Tissue Sarcoma |
| Therapeutic Pancreatic | VICCGI1173 07/31/2012 | A Phase 1 Study of Gemcitabine, Dasatinib and Erlotinib in Patients with Advanced Pancreatic Carcinoma |
| Therapeutic Leukemia | VICCBMT1190 07/25/2012 | Multi-Center Single Arm Phase II Study of Myeloablative Allogeneic Stem Cell Transplantation for Non-Remission Acute Myeloblastic Leukemia (AML) Using Clofarabine and Busulfan x 4 (CloBu4) Regimen |
| Therapeutic Leukemia; Pediatric Leukemia | VICCPED1186 06/11/2012 | CA180-372 / AALL1122 - A Phase 2 Multi-Center, Historically-Controlled Study of Dasatinib (IND# 66, 971) Added to Standard Chemotherapy in Pediatric Patients with Newly Diagnosed Philadelphia Chromosome Positive (Ph+) Acute Lymphoblastic Leukemia (ALL) |
| Therapeutic Breast | VICCBRE1202 05/04/2012 | A Phase Ib, Open-Label, Dose-Escalation Study of the Safety and Pharmacology of PI3-Kinase Inhibitor GDC-0941 in Combination with Paclitaxel, With and Without Bevacizumab or Trastuzumab, in Patients with Locally Recurrent or Metastatic Breast Cancer |
| Therapeutic Breast | VICCBRE1157 05/01/2012 | A Randomized Multicenter, Double-blind, Placebo-Controlled Comparison of Chemotherapy plus Trastuzumab plus Placebo versus Chemotherapy plus Trastuzumab plus Pertuzumab as Adjuvant Therapy in Patients with operable HER2-Positive Primary Breast Cancer |
| Therapeutic Breast | CTSUNSABPBREB-47-M 04/26/2012 | A Randomized Phase III Trial of Adjuvant Therapy Comparing Chemotherapy Alone (Six Cycles of Docetaxel Plus Cyclophosphamide or Four Cycles of Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel) to Chemotherapy Plus Trastuzumab in Women with Node-Positive or High-Risk Node-Negative HER2-Low Invasive Breast Cancer |
| Therapeutic Leukemia; Pediatric Leukemia | COGAALL1131 04/05/2012 | A Phase III Randomized Trial for Newly Diagnosed High Risk B-precursor Acute Lymphoblastic Leukemia (ALL) Testing Clofarabine (IND #73789, NSC# 606869) in the Very High Risk Stratum |
| Therapeutic Neuro-Oncology | VICCNEU1165 03/07/2012 | A Phase II Clinical Trial Evaluating DCVax?-Brain, Autologous Dendritic Cells Pulsed with Tumor Lysate Antigen for the Treatment of Glioblastoma Multiforme |
| Therapeutic Neuro-Oncology | COGACNS0822 02/13/2012 | A Randomized Phase II/III Study of Vorinostat (IND# 71976) and Local Irradiation OR Temozolomide and Local Irradiation OR Bevacizumab (IND# 7921) and Local Irradiation Followed by Maintenance Bevacizumab and Temozolomide in Children with Newly Diagnosed High-Grade Gliomas |
| Therapeutic Leukemia | ECOGHEME2906 01/20/2012 | Phase III Randomized Trial of Clofarabine as Induction and Post-Remission Therapy vs. Standard Daunorubicin & Cytarabine Induction and Intermediate Dose Cytarabine Post-Remission Therapy, Followed by Decitabine Maintenance vs. Observation in Newly-Diagnosed Acute Myeloid Leukemia in Older Adults (Age greater than or equal to 60 Years) |
| Therapeutic Breast | ECOGBRES1007 01/10/2012 | A Phase III, Randomized Clinical Trial of Standard Adjuvant Endocrine Therapy +/- Chemotherapy in Patients with 1-3 Positive Nodes, Hormone Receptor Positive and Her 2 Neu Negative Breast Cancer with Recurrence Score of 25 or Less. |
| Therapeutic Multiple Myeloma | VICCBMT1049 11/17/2011 | A Trial of Single Autologous Transplant with or without Consolidation Therapy versus Tandem Autologous Transplant with Lenalidomide Maintenance for Patients with Multiple Myeloma |
| Therapeutic Neuro-Oncology | COGACNS0821 10/08/2011 | ACNS0821 - Temozolomide with Irinotecan versus Temozolomide, Irinotecan plus Bevacizumab (NSC# 704865, BB-IND# 7921) for Recurrent/Refractory Medulloblastoma/CNS PNET of Childhood, A COG Randomized Phase II Screening Trial |
| Therapeutic Leukemia | ECOGBMTS0805 09/14/2011 | Phase II Study of Combination of Hyper-CVAD and Dasatinib (NSC-732517) With or Without Allogeneic Stem Cell Transplant in Patients with Philadelphia (Ph) Chromosome Positive and/or BCR-ABL Positive Acute Lymphoblastic Leukemia |
| Therapeutic Pediatric Leukemia | COGAAML1031 08/24/2011 | AAML1031 - A Phase III Randomized Trial for Patients with de novo AML using Bortezomib (IND# 58443, NSC# 681239) and Sorafenib (BAY 43-9006, IND# 69896, NSC# 724772) for Patients with High Allelic Ratio FLT3/ITD |
| Therapeutic Leukemia | VICCHEM1095 08/03/2011 | A Phase 3, Randomized, Controlled, Double-Blind, Multinational Clinical Study of the Efficacy and Safety of Vosaroxin and Cytarabine Versus Placebo and Cytarabine in Patients With First Relapsed or Refractory Acute Myeloid Leukemia (VALOR) |
| Therapeutic Non Small Cell | VICCTHO1079 07/27/2011 | Phase 3, Randomized, Open-Label Study of the Efficacy and Safety of Crizotinib versus Pemetrexed/Cisplatin or Pemetrexed/Carboplatin in Previously Untreated Patients with Non-Squamous Carcinoma of the Lung Harboring a Translocation or Inversion Event Involving the Anaplastic Lymphoma Kinase (ALK) Gene Locus |
| Therapeutic Lung; Non Small Cell | ECOGTHNE5508 06/29/2011 | Randomized Phase III Study of Maintenance Therapy with Bevacizumab, Premetrexed, or Combination of Bevacizumab and Premtrexed following Carboplatin, Paclitaxel and Bevacizumab for Advanced Non-Squamous NSCLC |
| Therapeutic Lymphoma | VICCDERM1059 06/01/2011 | Phase IV Randomized Study of Two Dose Levels of Targretin Capsules in Patients with Refractory Cutaneous T-Cell Lymphoma |
| Therapeutic Head/Neck; Neuro-Oncology | COGACNS0831 05/12/2011 | Phase III Randomized Trial of Post-Radiation Chemotherapy in Patients with Newly Diagnosed Ependymoma Ages 1 to 21 years. |
| Therapeutic Lymphoma | ECOGHEME2408 05/10/2011 | A 3-Arm Randomized Phase II Trial of Bendamustine-Rituximab (BR) Followed by Rituximab vs Bortezomib-BR (BVR) Followed by Rituximab vs BR Follwed by Lenalidomide/Rituximab in High Risk Follicular Lymphoma |
| Therapeutic Liver | CTSUGI80702-M 05/05/2011 | A Phase III Trial of 6 versus 12 Treatments of Adjuvant FOLFOX plus Celecoxib or placebo for patients with Resected Stage III Colon Cancer |
| Therapeutic Non Small Cell | ECOGTHO5508-M 02/09/2011 | Randomized Phase III Study of Maintenance Therapy with Bevacizumab, Pemetrexed, or a Combination of Bevacizumab and Pemetrexed Following Carboplatin, Paclitaxel and Bevacizumab for Advanced Non-Squamous NSCLC |
| Therapeutic Leukemia; Lymphoma; Pediatric Leukemia; Pediatric Lymphoma | COGAALL07P1 01/26/2011 | A Phase II Pilot Trial of Bortezomib (PS-341, Velcade, IND# 58,443) in Combination with Intensive Re-Induction Therapy for Children with Relapsed Acute Lymphoblastic Leukemia (ALL) and Lymphoblastic Lymphoma (LL) |
| Therapeutic Leukemia | VICCPHI1050 01/17/2011 | A Phase Ib, Dose-Finding Study of Oral Panobinostat (LBH589) in Combination with Idarubicin and Cytarabine Induction and High-Dose Cytarabine-Based Consolidation Therapy in Adult Patients Less and or Equal to 65 Years Old with Acute Myeloid Leukemia (AML) |
| Therapeutic Lung | ECOGTHO4508-M 12/07/2010 | Three-Arm Randomized Phase II Study of Carboplatin and Paclitaxel in Combination with Cetuximab, IMC-A12 or Both for Advanced Non-small Cell Lung Cancer Patients WhoWill Not Receive Bevacizumab-based Therapy |
| Therapeutic Breast | CTSUBREC40603-M 12/07/2010 | Randomized Phase II 2 X 2 Factorial Trial Of The Addition Of Carboplatin +/- Bevacizumab To Neoadjuvant Weekly Paclitaxel Followed By Dose-Dense AC In Hormone Receptor-Poor/HER2-Negative Resectable Breast Cancer |
| Therapeutic Liver | CTSUGIC80802-M 12/07/2010 | Phase III randomized study of sorafenib (IND 69896, NSC 724772) plus doxorubicin versus sorafenib in patients with advanced hepatocellular carcinoma (HCC) |
| Therapeutic Leukemia | COGAALL0932 11/11/2010 | Treatment of Patients with Newly Diagnosed Standard Risk B-Precursor Acute Lymphoblastic Leukemia (ALL) |
| Therapeutic Neuro-Oncology | ECOGNEUE3F05 09/16/2010 | Phase III Study of Radiation Therapy with or without Temozolomide for Symptomatic or Progressive Low-Grade Gliomas |
| Therapeutic Benign Hematologic | VICCNCPED1099 06/04/2010 | Nonmyeloablative Hematopoietic Cell Transplantation for Patients with Fanconi Anemia Using Alternative Marrow Donors: A Phase I/II Dose-Finding Study |
| Therapeutic Pancreatic | ACOSOGGIZ5041 04/14/2009 | A Phase II Study of Preoperative Gemcitabine and Erlotinib Plus Pancreatomy and Postoperative Gemcitabine and Erlotinib for Patients with Operable Pancreatic Adenocarcinoma. |
| Therapeutic Head/Neck | ECOGHNE1305 03/04/2009 | Phase III Randomized Trial of Chemotherapy With or Without Bevacizumab in Patients with Recurrent or Metastatic Head and Neck Cancer. |
| Therapeutic Head/Neck | ECOGHNE1305-M 02/11/2009 | A Phase III Randomized Trial of Chemotherapy with or without Bevacizumab in Patients with Recurrent or Metastatic Head and Neck Cancer |
| Therapeutic Prostate | ECOGUROE3805-M 09/17/2008 | CHAARTED: ChemoHormonal Therapy versus Androgen Ablation Randomized Trial for Extensive Disease in Prostate Cancer |
| Therapeutic Melanoma | VICCMEL0759 08/01/2008 | A Phase II Study of SU011248 in patients with metastatic mucosal or acral/lentiginous melanoma |
| Therapeutic Leukemia | VICCPED0801 06/06/2008 | Phase I Feasibility Study of Clofarabine and Low Dose Total Body Irradiation (TBI) as a Non-myeloablative Preparative Regimen for Stem Cell Transplantation (SCT) for Hematologic Malignancies: a Multi-Center Study |
| Therapeutic Prostate | CTSUUROC90203-M 11/05/2007 | A randomized Phase III Study of Neo-Adjuvant Docetaxel and Androgen Deprivation Prior to Prostatectomy Versus Immediate Radical Prostatectomy in Patients with High-Risk, Clinically Localized Prostate Cancer |
| Therapeutic Lung; Non Small Cell | VICCTHO0730 10/15/2007 | A Phase II Trial of Celecoxib plus Chemotherapy [Docetaxel or Pemetrexed] in Patients with Previously Treated, "COX Dependent" Recurrent Non-Small Cell Lung Cancer (SPORE) |
| Therapeutic Lung; Non Small Cell | ECOGTHOE1505 08/30/2007 | A Phase III Randomized Trial of Adjuvant Chemotherapy With or Without Bevacizumab for Patients With Completely Resected Stage IB (>=4 cm)-IIIA Non-Small Cell Lung Cancer (NSCLC). |
| Therapeutic Non Small Cell | ECOGTHOE1505-M 07/27/2007 | A Phase III Randomized Trial of Adjuvant Chemotherapy with or without Bevacizumab for Patients with Completely Resected Stage IB (> or = 4 cm)- IIIA Non-Small Cell Lung Cancer (NSCLC) |
| Therapeutic Benign Hematologic | VICCNCPED10101 12/28/2006 | Hematopoietic Cell Transplantation for Treatment of Patients with Primary Immunodeficiencies and Other Nonmalignant Inherited Disorders Using Low-Dose TBI and Fludarabine with or without Campath |
| Supportive-Therapeutic Leukemia | PRECOGHEM0901 12/04/2012 | Phase I Dose Finding/Phase II Placebo-Controlled Trial of Eltrombopag During Consolidation Therapy in Adults with Acute Myeloid Leukemia (AML) in Complete Remission |
You do not have JavaScript enabled. This site works better with JavaScript turned on.
